Tweet
<img alt="" height="1" width="1" />
Amgen: Vectibix fails in head and neck cancer test
BusinessWeek
Amgen Inc. said Wednesday its cancer drug Vectibix failed in a late-stage clinical trial, as it did not improve survival for patients with head and neck cancers compared to chemotherapy. Patients in the clinical trial were treated either with a ...
Amgen's Vectibix fails head-and-neck cancer trialReuters
Amgen drug flunks head-and-neck cancer trialFiercePharma
Amgen: Study Results 'Disappointing' For Cancer TreatmentNASDAQ
RTT News -PR Newswire (press release) -Stock Markets Review
all 32 news articles »
More...